# SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors

> **NCT01661283** · PHASE2 · COMPLETED · sponsor: **Sarcoma Alliance for Research through Collaboration** · enrollment: 25 (actual)

## Conditions studied

- Malignant Peripheral Nerve Sheath Tumors
- MPNST
- Sarcoma

## Interventions

- **DRUG:** everolimus
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT01661283
- **Lead sponsor:** Sarcoma Alliance for Research through Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2017-06
- **Final completion:** 2017-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-03-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01661283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01661283, "SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01661283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*